Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
November 7, 2018
Quarterly (Q3) results special: ATHX, BOLD, BLCM and GBT
November 6, 2018
Quarterly (Q3) results special: IONS, ONCE, QURE and VCEL
September 11, 2018
Regenerative Medicine Earnings Scorecard - Q2/18 - to date
August 17, 2018
Gene editing stocks, time to harvest some upside?
August 8, 2018
REGENXBIO (RGNX) proposes a $175 M offering
July 24, 2018
CRSPR stocks stay in the tank in another session…
July 23, 2018
CRSPR stocks stay in the tank …
July 2, 2018
MiMedx Group (MDXG) a BIG broom sweeps all...
July 2, 2018
BioLife Solutions (BLFS) reports Q2/18 – Blow-Out
5 hours 46 min ago
RegMed Investors’ (RMi) closing bell: What is not priced in?
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at firstname.lastname@example.org.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors